Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

February 28, 2027

Conditions
Heavy Menstrual BleedingUterine Fibroids
Interventions
DRUG

Relugolix

"* Relugolix (40 mg) tablet administered orally once daily;~* megestrol acetate (1 mg) administered orally once daily;~* medroxyprogesterone acetate (2 mg) administered orally once daily"

DRUG

Relugolix placebo

"Relugolix (0 mg) tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~megestrol acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor.~medroxyprogesterone acetate (0 mg) administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor."

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY